Global Erythropoietin Stimulating Agents Market is segmented By Product Type (Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Other), By Application (Cancer, Renal Disorders, Anti-Retroviral Treatment, Neural Diseases, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Erythropoietin Stimulating Agents Market Size
[150 Pages Report] The Global Erythropoietin Stimulating Agents Market reached USD 9.8 billion in 2022 and is expected to reach USD 19.2 billion by 2030 and is expected to grow with a CAGR of 8.9% during the forecast period 2023-2030.
It controls and regulates the mechanism of erythropoiesis in the bone marrow. Erythropoietin stimulating agents (ESAs) are useful for stimulating the growth of red blood cells. Erythropoietin stimulating agents are recommended to treat anemia due to chronic kidney failure, chemotherapy, and HIV. These stimulating agents are also useful for the treatment of reduced red blood cells during critical surgical procedures. The market is dominated by the availability of several erythropoietin stimulating agents such as epoetin-alfa, epoetin-beta, epoetin omega, epoetin delta, and darbepoetin-alpha.
Market Summary
| Metrics | Details |
| Market CAGR | 8.9% |
| Segments Covered | By Product Type, By Application, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Get a Free Sample Click here
Market Dynamics
The market is driven by the growing demand for erythropoietin stimulating agents (ESAs) with the increasing prevalence of anemia. According to the World Vision Organization, more than 2 billion people are suffering from anemia worldwide. Males and females of all ages are affected by anemia. It is most common among pregnant women and young children. Iron deficiency is the major cause of anemia and insufficient red blood cell production. Several parasite infections, such as Ascaris, schistosomiasis, and hookworms, lower the hemoglobin (Hb) concentration in the blood. There is growing usage of the erythropoietin stimulating agents among patients with HIV infections, cancer, and end-stage renal disorder. The increase in the number of people undergoing surgeries shall stimulate market growth. The people undergoing the surgeries are at high risk of developing thrombosis.
There is an increase in the approval of the erythropoietin stimulating agents. For instance, in September 2019, JCR Pharmaceuticals Co., Ltd. and Kissei Pharmaceutical Co., Ltd. had received the Darbepoetin Alfa BS Injection JCR, a long-acting erythropoiesis-stimulating agent in Japan. The Phase III study demonstrated the equivalence in efficacy and safety compared with Darbepoetin alpha (innovator product), along with the similarity in the safety profile.
In June 2018, Vifor Pharma Inc. had received the approval for Mircera (methoxy polyethylene glycol-epoetin beta) from the United States Food and Drug Administration (FDA) for the pediatric patients 5 to 17 years of age on hemodialysis who are converting from another ESA after their hemoglobin level was stabilized with an ESA.
Market Segment Analysis
The global erythropoietin stimulating agents market is segmented based on product type as the epoetin alfa, epoetin beta, darbepoetin alfa, etc. Epoetin alfa is the human erythropoietin produced in cell culture with the help of recombinant DNA technology. Epoetin alfa is used for the treatment of anemia among people with kidney disease. It is effective for treating anemia occurred due to chemotherapy treatments. It is not recommended for patients with cancers that originate in the bone marrow, such as acute myelogenous leukemia. It is also used among anemic patients with a high risk of blood loss to reduce the need for blood transfusions before the planned surgeries. It is not preferred to treat anemia from other causes such as iron or folate deficiency or gastrointestinal bleeding. It acts by signaling the bone marrow to make more red blood cells. The growing incidence of cancer shall stimulate market growth.
Further, the market is also classified based on cancer, renal disorders, anti-retroviral treatment, neural diseases, and others. The cancer segment accounts for the highest market share due to the growing usage of the erythropoietin stimulating agents to treat anemic patients being treated with chemotherapy. Around 75% of anemia cases occurred due to cancer chemotherapy. The studies have demonstrated that the use of erythropoietin stimulating agents effectively improves the quality of life among patients. Erythropoietin stimulating agents work by targeting the major cause of anemia in cancer patients undergoing chemotherapy against the myelosuppression and endogenous erythropoietin deficiency. Epoetin alfa and epoetin beta are the most recommended erythropoietin stimulating agents for cancer-related anemia. Procrit, Epogen, and NeoRecormon are the widely used erythropoietin stimulating agents.
Market Geographical Share
By region, the global erythropoietin stimulating agents market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global erythropoietin stimulating agents market and expected to grow at the highest CAGR during the forecasted period due to the high prevalence of chronic diseases such as cancer, renal disorders, neural diseases, chronic kidney disease, and others. According to the Centres for Disease Control and Prevention (CDC), around 37 million people suffer from Chronic Kidney Disease. Chronic Kidney Disease is most common among people aged 65 years or older. There is a presence of a large number of companies developing erythropoietin stimulating agents. There is an increasing launch of biosimilars with enhanced efficacy, enhanced therapeutic effect, and cost-effectiveness. There are increasing research and development activities for innovative molecules. Several companies are focusing on discovering new therapeutic areas for existing drugs.
Companies and Competitive Landscape
The global erythropoietin stimulating agents market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Amgen Inc., Biocon Limited, Celltrion Inc., F. Hoffmann-La Roche Ltd, Intas Pharmaceuticals Ltd, Johnson and Johnson, Pfizer Inc., Teva Pharmaceutical Industries Ltd, and Thermo Fisher Scientific are the leading market players with significant market share.
The major players are using product development, product launch, product approval, market expansion, and capacity utilization strategies for holding their market position. For instance, in May 2018, Pfizer Inc. had received approval for Retacrit (epoetin alfa-EPBX), a biosimilar to Epogen and Procrit (epoetin alfa) from the United States Food and Drug Administration (FDA) for all indications of the reference product. Retacrit is the biosimilar erythropoiesis-stimulating agent (ESA). Retacrit may provide patients and their physicians with increased access to a high-quality, lower-cost alternative treatment option for anemia and reduce allogeneic red blood cell (RBC) transfusions in certain patients. Retacrit is indicated for the treatment of Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis, Zidovudine in HIV-infected patients, and concomitant effects myelosuppressive chemotherapy, and reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery.
In March 2018, Chugai Pharmaceutical Co., Ltd. had received approval for Mircera Injection Syringe 12.5μg from the Ministry of Health, Labour, and Welfare to treat renal anemia in Japan. Mircera is a long-acting erythropoiesis-stimulating agent that raises the stability of epoetin beta in the bloodstream through pegylation. It stimulates erythropoiesis by a different interaction with the erythropoietin receptor on progenitor cells in the bone marrow and enables stable and sustained control of anemia.
Several companies are entering into collaborations, acquisitions, mergers, and licensing activities. For instance, in January 2017, Amgen had entered into six-year sourcing and supply agreement with DaVita Inc. Under the terms of the new agreement, Amgen would supply DaVita with Epogen (epoetin alfa) and Aranesp (darbepoetin alfa) in amounts necessary to meet a specified annual percentage of DaVita's and its affiliates' requirements for erythropoiesis-stimulating agents used in providing dialysis services in the United States and Puerto Rico.
In May 2016, Vifor Pharma, a company of the Galenica Group, had expanded its erythropoiesis-stimulating agent (ESA) portfolio with the licensing of commercialization rights in the United States dialysis market to Pfizer’s Retacrit, a proposed biosimilar epoetin, in the field of nephrology.
In May 2015, Roche had entered into an exclusive license agreement to commercialize Roche’s drug Mircera in the United States and Puerto Rico. Under the terms of the agreement, Galenica has the exclusive right to commercialize Mircera in the United States and Puerto Rico. Roche would manufacture and supply Mircera to Galenica. Roche would receive upfront and milestone payments, supply reimbursements, and tiered royalties on Mircera sales in the United States and Puerto Rico.
